Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: Indication of anti-CMV activity with low toxicity

Journal of Medicine

Volumn 28, Issue 1-2, 1997, Pages 108-128

  Gordon, Maxwell ^a,g   Deeks, Steven ^b   De Marzo, Charles ^c   Goodgame, Jeff ^c   Guralnik, Mario ^a   Lang, William ^d   Mimura, Tohru ^e   Pearce, Daniel ^f   Kaneko, Yutaro ^e  

^a AJI Pharma USA Inc   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c Goodgame Medical Group   (United States)

^d ViRx Inc   (United States)

^e AJINOMOTO CO INC   (Japan)

^f CSI   (United States)

^g NONE   (United States)

Author keywords

Anti cytomegalovirus activity; Curdlan sulfate; Cytomegalovirus; Drug tolerance; Human immunodeficiency virus

Indexed keywords

CURDLAN; DEXTRAN SULFATE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG TOLERANCE; EARLY DIAGNOSIS; ENZYME INHIBITION; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; BETA-GLUCANS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS INFECTIONS; DRUG TOLERANCE; FEMALE; GLUCANS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 0030835882     PISSN: 00257850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Abrams, D.I., Kuno, S., Wong, R., Jeffords, K. et al. (1989).: Oral dextran sulfate in the treatment of AIDS and AIDS-related complex. Ann Interm. Med. 110: 183-188.
2. Aoki, T., Kaneko, Y. Ngugen, T. et al. (1992).: In vitro long-term treatment of HIV-1 infection with curdlan sulfate. AIDS Res. Hum. Retrovirus 8: 605-612.
3. Aoki, T., Kaneko, Y., Stefanski, M.S., Nguyen, T. and Ting, R.C.Y. (1991).: I. Inhibitory effects of curdlan sulfate on HIV-1 infection. AIDS Res. Human Retrovirus 7: 409-415.
4. Baba, M., Nakajima, M., Schlos, D. et al. (1988b).: Pentosan polysulfate, a sulfated polysaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res. 9: 335-343.
5. Baba, M., Snoeck, R., Pauwels, R. and De Clercq, E. (1988).: Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including HSV, CMV, VSV and HIV. Antimicrob. Agents Chemother. 32: 1742-1745.
6. Biesert, L., Adamski, M., Zimmer, G. et al. (1990).: Anti-human immunodeficiency virus (HIV) drug HOE/BAY 946 increases membrane hydrophobicity of human lymphocytes and specifically suppresses HIV-protein synthesis. Med. Microbiol. Immunol. 179: 307-321.
7. Butcher, E.C. and Picher, L.J. (1996).: Lymphocyte homing and hemeostasis. Science 272: 60-66.
8. Flexner, C., Barditch-Crovo, P.A., Kornhauser, D.M. and Leitner, P.S. (1991).: Pharmacokinetics, toxicity and activity of intravenous dextran sulfate in HIV. Antimicrob. Agents Chemother. 35: 2544-2550.
9. Gordon, M., Guralnik, M., Kaneko, Y. et al. (1994).: Phase I study of curdlan sulfate - a HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes. J. Med. 25: 103-180.
10. Gordon, M., Guralnik, M., Kaneko, Y., Mimura, T., Goodgame, J., and Lang, W. (1995).: Further clinical studies of curdlan sulfate (CRDS) - an anti-HIV agent. J. Med. 26: 97-131.
11. Harda, S., Koyanagi, Y. and Yamamoto, N. (1985).: Infection of HTLV-III/LAV in HTLV-1-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229: 536-566.
12. Herdewijn, P. (1988).: New chemical compounds with antiviral action. Verh. K. Acad. Geneeskd. Bldg. 50: 349-365.
13. Ito, M., Baba, M., Sato, A. et al. (1987).: Inhibitory effect of dextran sulfate and heparin on the replication of HIV in vitro. Antiviral Res. 7: 361-367.
14. Jagodzinski, P.P., Wiaderkiewicz, R., Kurzawski, G., Kloczewiak, M., Nakashima, H., Hyjek, E., Yamamoto, N., Uryu, T., Kaneko, Y., Posner, M.R. and Kozbor, D. (1994).: Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro. Virology 202: 735-745.
15. Kaneko, Y., Yoshida, O., Nakagawa, R., Yoshida, T., Date, M., Ogihara, S., Shioga, S., Matsuzawa, Y., Nagashima, N., Irie, Y., Mimura, T., Shinkai, H., Yasuda, N., Matsuzaki, K., Uryu, T. and Yamamoto, N. (1990).: Inhibition of HIV-1 infectivity with curdlan sulfate in vitro. Biochem. Pharmacol. 39: 793-797.
16. Masihi, K.N., Chihara, G., and Kaneko, Y. (1994).: Inhibition of TNF production by lentinan and curdlan sulfate. In: Tenth International Conference on AIDS 1994; PA0261 (p. 95 in Abstract Book, Volume 2) Yokohama, Japan.
17. Nakashima, H., Yoshida, O., Tochikuro, T.S., Kaneko, Y. et al. (1987).: Sulfation of polysaccharide generate potent and selective inhibitors of HIV infection and replication in vitro. Jpn. J. Cancer Res. 78: 1164-1168.
18. Nieto, F.J., Adam, E., Sorlie, P., Farzadegan, H., Melnick, J.L., Comstock, G.W., and Szyklo, M.. (1996).: Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 94: 922-927.
19. Patel, M., Yanogishita, M., Roderiguez, G. et al. (1993).: Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retrovirus 9: 167-174.
20. Voss, H., Serisch, K.H. and Panse, P. (1974).: Sulfated glylosaminoglycans as virus inhibitors. Zentral Bl. Bacteriol. Orig. A. 229: 1-36.
21. Yoshida, O., Nakashima, H., Yoshida, T., Kaneko, Y., et al. (1988).: Sulfation of the immunomodulating polysaccharide lentinan: a novel strategy for antivirals to human immunodeficiency virus (HIV). Biochem. Pharmacol. 37: 2887-2891.
22. Zhou, Y.F., Leon, M.B., Waclawiw, M.A., Popma, J.J., Yu, Z.X., Finkel, T. and Epstein, S.E. (1996).: Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. Circulation 335: 624-630.